These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 3297316)
1. Early parkinsonism. Calne DB; Stoessl AJ Clin Neuropharmacol; 1986; 9 Suppl 2():S3-8. PubMed ID: 3297316 [TBL] [Abstract][Full Text] [Related]
2. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals. Kopin IJ Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621 [No Abstract] [Full Text] [Related]
3. Parkinson's disease in 1984: an update. Lang AE; Blair RD Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779 [TBL] [Abstract][Full Text] [Related]
4. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985. J Neural Transm Suppl; 1986; 20():1-81. PubMed ID: 3489069 [No Abstract] [Full Text] [Related]
5. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): one designer drug and serendipity. Weingarten HL J Forensic Sci; 1988 Mar; 33(2):588-95. PubMed ID: 3259617 [TBL] [Abstract][Full Text] [Related]
10. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin]. Hirata Y; Nagatsu T Tanpakushitsu Kakusan Koso; 1986 Apr; 31(5):398-409. PubMed ID: 3520683 [No Abstract] [Full Text] [Related]
11. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism. Kito S; Miyoshi R; Mizuno K; Nitta K; Matsubayashi H; Yamamura Y; Tahara E Adv Neurol; 1987; 45():159-65. PubMed ID: 2881441 [No Abstract] [Full Text] [Related]
12. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Doty RL; Singh A; Tetrud J; Langston JW Ann Neurol; 1992 Jul; 32(1):97-100. PubMed ID: 1642478 [TBL] [Abstract][Full Text] [Related]
13. The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by MPTP. Eldridge R; Rocca WA N Engl J Med; 1985 Oct; 313(18):1159-60. PubMed ID: 3876508 [No Abstract] [Full Text] [Related]
14. Secondary (toxic) parkinsonism as model of Parkinson's disease. Riederer P; Sofic E; Heuschneider G; Benedetti MS; Dostert P Funct Neurol; 1988; 3(4):449-57. PubMed ID: 3072280 [No Abstract] [Full Text] [Related]
15. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease]. Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199 [TBL] [Abstract][Full Text] [Related]
16. [Parkinsonism and MPTP (methylphenyltetrahydropyridine)]. Nagatsu T No To Shinkei; 1986 Jul; 38(7):706-7. PubMed ID: 3489476 [No Abstract] [Full Text] [Related]
17. Development of new pharmacological approaches in Parkinson's disease. Carlsson A Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631 [No Abstract] [Full Text] [Related]